Insulin-like growth factor-1 and progression of motor symptoms in early, drug-naïve Parkinson's disease

Journal of Neurology

Volumn 260, Issue 7, 2013, Pages 1724-1730

  Picillo, Marina ^a   Erro, Roberto ^a   Santangelo, Gabriella ^b,c   Pivonello, Rosario ^a   Longo, Katia ^c   Pivonello, Claudia ^a   Vitale, Carmine ^c,d   Amboni, Marianna ^c   Moccia, Marcello ^a   Colao, Annamaria ^a   Barone, Paolo ^e   Pellecchia, Maria Teresa ^e  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c IDC Hermitage Capodimonte   (Italy)

^d UNIVERSITY OF NAPLES PARTHENOPE   (Italy)

^e UNIVERSITY OF SALERNO   (Italy)

Author keywords

IGF 1; Motor symptoms; Parkinson's disease; Progression

Indexed keywords

SOMATOMEDIN C;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYMPTOMATOLOGY; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 84880293002     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-013-6851-0     Document Type: Article

References (29)

1. Braak H, Del Tredici K, Rub U et al (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211
2. Guan J, Krishnamurthi R, Waldvogel HJ et al (2000) N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats. Brain Res 859:286e92
3. Quesada A, Lee BY, Micevych PE (2008) PI3 kinase/Akt activation mediates estrogen and IGF-1 nigral DA neuronal neuroprotection against a unilateral rat model of Parkinson's disease. Dev Neurobiol 68:632e44
4. Offen D, Shtaif B, Hadad D et al (2001) Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson's disease. Neurosci Lett 316:129e32
5. Sutherland GT, Matigian NA, Chalk AM et al (2009) A cross-study transcriptional analysis of Parkinson's disease. PLoS ONE 4(3):e4955
6. Godau J, Herfurth M, Kattner B, Gasser T, Berg D (2010) Increased serum insulin-like growth factor 1 in early idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 81:536-538
7. Godau J, Knauel K, Weber K et al (2011) Serum insulin-like growth factor 1 as possible marker for risk and early diagnosis of Parkinson disease. Arch Neurol 68:925-931
8. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinic-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181-184
9. Gilman S, Wenning GK, Low PA et al (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71(9):670-676
10. Litvan I, Agid Y, Calne D et al (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology 47(1):1-9
11. Lang AE, Riley DE, Bergeron C (1994) Cortical-basal ganglionic degeneration. In: Calne DB (ed) Neurodegenerative diseases. WB Saunders, Philadelphia, pp 877-894
12. McKeith IG, Galasko D, Kosaka K et al (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47(5):1113-1124
13. Fonseca VA (2010) Effects of beta-blockers on glucose and lipid metabolism. Curr Med Res Opin 26(3):615-629
14. Unterman TG, Jentel JJ, Oehler DT et al (1993) Effects of glucocorticoids on circulating levels and hepatic expression of insulin-like growth factor (IGF)-binding proteins and IGF-I in the adrenalectomized streptozotocin-diabetic rat. Endocrinology 133(6):2531-2539
15. Frystyk J, Schou AJ, Heuck C et al (2012) Prednisolone reduces the ability of serum to activate the IGF1 receptor in vitro without affecting circulating total or free IGF1. Eur J Endocrinol 168(1):1-8
16. De Hert M, Detraux J, van Winkel R et al (2011) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8(2):114-126
17. Tomlinson CL, Stowel L, Patel S et al (2010) Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord 25(15):2649-2653
18. Fahn S, Elton R: Members of the UPDRS Development Committee (1987) The unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M (eds) Recent developments in Parkinson's disease, vol 2. Macmillan Health Care Information, Florham Park, pp 153-163, 293-304
19. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427-442
20. Levy G, Louis ED, Cote L et al (2005) Contribution of aging to the severity of different motor signs in Parkinson disease. Arch Neurol 62:467-472
21. Jankovic J, McDermott M, Carter J et al (1990) Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson study group. Neurology 40:1529-1534
22. Evans JR, Mason SL, Williams-Gray CH et al (2011) The natural history of treated Parkinson's disease in an incident, community based cohort. J Neurol Neurosurg Psychiatry 82(10):1112-1118
23. Schrag A, Spottke A, Quinn NP et al (2009) Comparative responsiveness of Parkinson's disease scales to change over time. Mov Disord 24:813e18
24. Salehi Z, Mashayekhi F, Naji M (2008) Insulin like growth factor-1 and insulin like growth factor binding proteins in the cerebrospinal fluid and serum from patients with Alzheimer's disease. BioFactors 33(2):99-106
25. Vardy ER, Rice PJ, Bowie PC, Holmes JD, Grant PJ, Hooper NM (2007) Increased circulating insulin-like growth factor-1 in late-onset Alzheimer's disease. J Alzheimers Dis 12(4):285-290
26. Wickremaratchi MM, Knipe MD, Sastry BS et al (2011) The motor phenotype of Parkinson's disease in relation to age at onset. Mov Disord 26(3):457-463
27. Ransmayr G, Künig G, Neubauer M et al (1995) Effect of age and disease duration on parkinsonian motor scores under levodopa therapy. J Neural Transm Park Dis Dement Sect 9(2-3):177-188
28. Helmich RC, Hallett M, Deuschl G, Toni I, Bloem BR et al (2012) Cerebral causes and consequences of parkinsonian resting tremor: a tale of two circuits? Brain 135((Pt 11)):3206-3226
29. Post B, Muslimovic D, van Geloven N et al (2011) Progression and prognostic factors of motor impairment, disability and quality of life in newly diagnosed Parkinson's disease. Mov Disord 26(3):449-456